Medical treatment for active breast cancer brain metastases
Mené en Chine sur 78 patientes atteintes d'un cancer du sein HER2+ et présentant des métastatases cérébrales (durée médiane de suivi : 15,7 mois), cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse objective intracrânienne, et la toxicité d'un traitement combinant pyrotinib et capécitabine
Metastatic breast cancer is the second most common cause of brain metastases. In the ESME cohort, the risk of developing brain metastases during metastatic diseasewas 34% for patients with ER-positive and HER2-positive breast cancer and 49% forpatients with ER-negative and HER2-positive breast cancer. Brain metastases are associated with decreased quality of life and overall survival.Current recommendations principally rely on surgery and radiotherapy for control ofbrain metastases, with medical treatment mostly considered after failure of such interventions.
The Lancet Oncology , commentaire, 2021